Reviva Pharmaceuticals Holdings Inc (NAS:RVPH)

$ 1.37 0.03 (2.24%) Market Cap: 38.25 Mil Enterprise Value: 25.77 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Reviva Pharmaceuticals Holdings, Inc. Phase 3 RECOVER Topline Results Call Transcript
Oct 30, 2023
Reviva Pharmaceuticals Holdings, Inc. at Canaccord Genuity Growth Conference Transcript
Aug 10, 2023
Reviva Pharmaceuticals Holdings, Inc. at Lytham Partners Spring Investor Conference (Virtual) Panel Transcript
May 18, 2023
Reviva Pharmaceuticals Holdings, Inc. at Lytham Partners Spring Investor Conference (Virtual) Transcript
May 18, 2023
Reviva Pharmaceuticals Holdings, Inc. to Host Key Opinion Leader Webinar Transcript
May 02, 2023
Reviva Pharmaceuticals Holdings, Inc. at ROTH Conference Transcript
Mar 13, 2023
Reviva Pharmaceuticals Holdings, Inc. at Lytham Partners Fall Investor Conference (Virtual) Transcript
Sep 28, 2022
Reviva Pharmaceuticals Holdings, Inc. at OTC Markets Life Sciences Virtual Investor Forum Transcript
Jun 23, 2022
Reviva Pharmaceuticals Holdings, Inc. to Host Key Opinion Leader Webinar for Schizophrenia and Other Neuropsychiatric Disorders Call Transcript
May 03, 2022
Reviva Pharmaceuticals Holdings, Inc. at Benzinga Healthcare Small Cap Conference (Virtual) Transcript
Sep 29, 2021

Reviva Pharmaceuticals Holdings, Inc. to Host Key Opinion Leader Webinar for Schizophrenia and Other Neuropsychiatric Disorders Call Transcript

May 03, 2022 / 02:00PM GMT

Release Date Price: $1.95 (+1.04%)

Transcript 10-Q8-K

Unidentified Participant

Good morning and welcome to the Reviva Pharmaceuticals' KOL webinar on antipsychotic drugs for schizophrenia and other neuropsychiatric disorders. (Operator Instructions). As a reminder, this call is being recorded and a replay will be made available on the Reviva website following the conclusion of the event.

I'd now like to turn the call over to your host, Dr. Lax Bhat, Founder, President and Chief Executive Officer of Reviva Pharmaceuticals. Please go ahead, Lax.

Lax Bhat

Reviva Pharmaceuticals Holdings, Inc. - Founder, President & CEO

Thank you, Tara. Good morning, thank you to each and every one of you for being with us today. It's my pleasure to welcome everyone to our key opinion leader webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders. So, today's webinar has four segments. The first segment, our KOL, Dr. Citrome will present an overview of antipsychotic treatment in individuals with schizophrenia and other disorders.

In the second segment our KOL, Dr. Ereshefsky will present

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.